Companies › CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
4 active drug programs in 7 registered trials: 3 Phase 1, 2 Phase 2, 2 Phase 3; Other, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SYH2053 Injection | – | Phase 3 | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia; Heterozygous Familial Hypercholesterolemia (HeFH) | Dec 2027 |
| SYH2070 injection PCSK9 inhibitor | – | Phase 2 | Mixed Hyperlipidemia; Diagnosed With HoFH; Healthy Subjects (HS) | Apr 2027 |
| SYH2061 | – | Phase 1 | Healthy Subjects | Nov 2026 |
| SYH2062 injection | – | Phase 1 | Healthy Chinese Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06842537 | SYH2062 injection | Phase 1 | Healthy Chinese Volunteers | Other | Dec 2025 |
| NCT07241910 | SYH2061 | Phase 1 | Healthy Subjects | Other | Nov 2026 |
| NCT07695597 | SYH2070 injection | Phase 2 | Mixed Hyperlipidemia | Metabolic and endocrine | Apr 2027 |
| NCT07591298 | SYH2070 injection | Phase 2 | Diagnosed With HoFH | Metabolic and endocrine | Sep 2027 |
| NCT07241923 | SYH2070 injection | Phase 1 | Healthy Subjects (HS) | Other | Nov 2027 |
| NCT07421297 | SYH2053 Injection | Phase 3 | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Metabolic and endocrine | Dec 2027 |
| NCT07465263 | SYH2053 Injection | Phase 3 | Heterozygous Familial Hypercholesterolemia (HeFH) | Metabolic and endocrine | Feb 2028 |
No annotated target.
–
OPKO Health Beijing QL Biopharmaceutical Energenesis Biomedical BrightGene Bio-Medical Technology Tortugas Neuroscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.